The Claim

In diet-induced obese mice treated with semaglutide or tirzepatide for 4–14 days, absolute muscle mass decreases by 5–10%, relative muscle mass (muscle-to-body-weight ratio) increases by 15–25%, and muscle strength relative to body weight improves, with no greater loss than in calorie-matched controls, indicating that muscle loss is proportional to overall weight reduction rather than drug-specific.

Source: Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
56score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In obese mice treated with semaglutide or tirzepatide for 4–14 days, total muscle mass decreases by 5–10%, but the proportion of muscle relative to body weight increases by 15–25%, and muscle strength relative to body weight improves. The amount of muscle lost is no greater than in mice that ate the same number of calories without the drugs.

See the scientific wording

In diet-induced obese mice treated with semaglutide or tirzepatide for 4–14 days, absolute muscle mass decreases by 5–10%, but relative muscle mass (muscle-to-body-weight ratio) increases by 15–25%, and muscle strength relative to body weight improves, with no greater loss than in calorie-matched controls, indicating that muscle loss is proportional to overall weight reduction rather than drug-specific.

Why this might work

When the body loses weight, fat tissue shrinks faster than muscle tissue, so muscles make up a larger portion of the body. This makes muscles stronger relative to the total body weight, even if they get slightly smaller.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans

    When obese mice lose weight with these drugs, they lose mostly fat, not muscle—so their muscles become a bigger part of their body and work better relative to their size. Dieting alone causes the same effect, so the drugs aren’t harming muscles more than just eating less.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.